Influenza symptoms and their impact on elderly adults: Randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines

Influenza and other Respiratory Viruses

Volumn 8, Issue 4, 2014, Pages 452-462

  van Essen, Gerrit A ^a   Beran, Jiri ^b   Devaster, Jeanne Marie ^c   Durand, Christelle ^c   Duval, Xavier ^d   Esen, Meral ^e   Falsey, Ann R ^f   Feldman, Gregory ^g   Gervais, Pierre ^h   Innis, Bruce L ⁱ   Kovac, Martina ^c   Launay, Odile ^j,k,l   Leroux Roels, Geert ^m   Mcelhaney, Janet E ⁿ   Mcneil, Shelly ^o   Oujaa, Mohammed ^c   Richardus, Jan Hendrik ^p   Ruiz Palacios, Guillermo ^q   Osborne, Richard H ^r,s   Oostvogels, Lidia ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Vaccination and Travel Medicine Centre   (Czech Republic)

^c GSK   (Belgium)

^d BICHAT HOSPITAL   (France)

^e Institut fur Tropenmedizin   (Germany)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g S Carolina Pharmaceutical Research   (United States)

^h QandT Research   (Canada)

ⁱ GLAXOSMITHKLINE   (United States)

^j INSERM   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m GHENT UNIVERSITY   (Belgium)

ⁿ HSN Volunteer Association Chair in Geriatric Research Advanced Medical Research Institute of Canada   (Canada)

^o DALHOUSIE UNIVERSITY   (Canada)

^p Public Health Service of the Rotterdam Region   (Netherlands)

^q INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^r DEAKIN UNIVERSITY   (Australia)

^s Measured Solutions for Health (MESH) P L   (Australia)

more..

Author keywords

AS03 adjuvanted vaccine; Elderly; FluiiQ; Influenza; Patient reported outcomes

Indexed keywords

AS03 ADJUVANTED INACTIVATED TRIVALENT SPLIT VIRION INFLUENZA VACCINE; INFLUENZA VACCINE; TRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; SQUALENE;

AGED; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE BLIND PROCEDURE; THROAT CULTURE; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA, HUMAN; PATHOLOGY; QUESTIONNAIRE; TREATMENT OUTCOME; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; QUESTIONNAIRES; SINGLE-BLIND METHOD; SQUALENE; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 84902364106     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12245     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-1062.
2. Pitman RJ, Melegaro A, Gelb D, Siddiqui MR, Gay NJ, Edmunds WJ. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007; 54:530-538.
3. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-1340.
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44.
5. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010; 2:CD004876.
6. Langley JM, Risi G, Caldwell M et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729-1738.
7. Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-589.
8. Heijmans S, De Meulemeester M, Reynders P et al. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054-1062.
9. Lasko B, Reich D, Madan A, Roman F, Li P, Vaughn D. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 2011; 204:574-581.
10. Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91-101.
11. Van Buynder PG, Konrad S, Van Buynder JL et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31:6122-6128.
12. Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm193282.pdf (Accessed 7 February 2013).
13. Osborne RH, Norquist JM, Elsworth GR et al. Development and validation of the Influenza Intensity and Impact Questionnaire (FluiiQ™). Value Health 2011; 14:687-699.
14. McElhaney JE, Beran J, Devaster J-M et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485-496.
15. Vesikari T, Beran J, Durviaux S et al. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol 2012; 53:22-28.
16. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Series B Stat Methodol 1977; 39:1-38.
17. Schafer JL. Analysis of incomplete multivariate data, Monographs on Statistics and Applied Probability 72. London: Chapman & Hall, 1997.
18. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S. Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 2013; 22:475-483.
19. Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4:70.
20. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR; Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77:371-383.
21. Center for Infectious Disease Research and Policy (CIDRAP). The compelling need for game-changing influenza vaccines. An analysis of the influenza vaccine enterprise and recommendations for the future. October 2012. Available at www.cidrap.umn.edu (Accessed 20 November 2012).
22. Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. JAMA 2004; 292:2115-2124.
23. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176:6333-6339.